ALS Center of Excellence https://www.umich-als.org Pranger ALS Clinic Wed, 14 Jun 2023 15:48:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.2 https://www.umich-als.org/wp-content/uploads/2019/11/cropped-download-32x32.png ALS Center of Excellence https://www.umich-als.org 32 32 159626766 MedSciWriters Features Dr. Feldman in Scientist Spotlight https://www.umich-als.org/medsciwriters-features-dr-feldman-in-scientist-spotlight/ Wed, 31 May 2023 15:39:55 +0000 https://www.umich-als.org/?p=2103

For ALS Awareness Month (May), the University of Michigan student organization chose Eva Feldman, M.D., Ph.D., to appear in their “Scientist Spotlight” feature to talk about the disease.

Scientist Spotlight: Dr. Eva Feldman

Written by: Isha Verma

Edited by: Jennifer Baker

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig’s disease, is a neurological disease that causes the degeneration and death of the nerves controlling the muscles, called motor neurons. This results in gradual muscle wasting and loss of the ability to walk, talk, eat, and, eventually, breathe. The typical survival is 3 to 5 years from the onset of symptoms. ALS occurs in approximately 1 to 4 of every 100,000 individuals, and over 30,000 individuals in the United States are estimated to be living with ALS.

The cause of ALS remains unknown. About 90% of the individuals suffer from the ‘sporadic’ form of ALS, with no family history and no single gene mutation underlying the disorder. Sporadic ALS is believed to be related to the complex interplay of genetics and environmental exposures, which makes a person more susceptible to a neurological disease. In about 10% of the patients, the disease is inherited and called ‘familial’ ALS. Mutations in more than 20 genes, including chromosome 9 open reading frame 72 (C9orf72) and copper-zinc superoxide dismutase 1 (SOD1), have been linked with ALS. Whether ALS is sporadic or familial, there are currently no effective treatments.

In honor of ALS Awareness Month (May), we focus on Dr. Eva Feldman, an internationally acclaimed clinician-scientist working on developing new cures and treatments for ALS.

Dr. Eva Feldman is the James W. Albers Distinguished Professor of Neurology at the University of Michigan Medical School. She is the Director of the ALS Center of Excellence and the NeuroNetwork for Emerging Therapies and the Past President of the American Neurological Association and the Peripheral Nerve Society. Dr. Feldman has received many honors, including induction into the prestigious National Academy of Medicine. In addition, she was elected to the Honorary Association of American Physicians, the Johns Hopkins Society of Scholars, and was named as one of the country’s top physicians by Castle-Connolly in 2016.

photo of Dr. Eva Feldman

Dr. Eva Feldman

Dr. Feldman’s research in ALS spans a broad range of topics, including gene discovery, stem cell therapeutics, the role of environmental toxins on disease progression, and the repurposing of existing drugs as new therapies in ALS. The main focus of Dr. Feldman’s lab is to understand the environmental contribution to the pathogenesis of ALS. Her research group showed that persistent organic pollutants are found in high concentrations in the plasma of ALS patients and negatively impact ALS survival, emphasizing the effect of environmental exposure on ALS pathogenesis. Dr. Feldman’s team has also found that ALS patients have high occupational exposure to particulate matter, volatile organic compounds, metals, pesticides, and combustion and diesel exhaust. The same study showed that people working in production occupations had a higher risk of ALS. This may help explain why the Midwest, which has the largest number of individuals in production occupations, has the highest prevalence of ALS in the United States.

Another important focus of research in the Feldman lab is understanding the specific immune signatures in ALS patients to identify novel targets for drug therapy. For example, Dr. Feldman’s team has identified differences between the immune systems of male and female ALS patients, which could have important clinical implications. The team is also working on developing drugs against natural killer cells. Under normal conditions, natural killer cells are essential for attacking cancerous and infected cells in the body. However, in ALS, natural killer cells mistakenly target motor neurons and activate other immune cells, resulting in disease progression. To shut down natural killer cells’ harmful attack on motor neurons, Dr. Feldman’s team is trying to repurpose tofacitinib, a drug used for rheumatoid arthritis treatment, for ALS. Tofacitinib blocks natural killer cell activity, reducing their killing potential and ability to produce destructive signals. If successful, this drug could delay the progression of nerve cell degeneration in ALS. Dr. Feldman’s group has also submitted a patent to repurpose FDA-approved drugs known as Jak kinase inhibitors for ALS patients to block natural killer cell activity and potentially slow ALS progression.

The ALS Center of Excellence, of which Dr. Feldman is Director, is also working on understanding the role of abnormalities in the metabolism, processing, and recycling of ribonucleic acid (RNA) in ALS-associated nerve cell degeneration. The team is studying the role of exosomes that may travel between nerve cells and transport the damaged molecules required for the progression of some forms of ALS. Dr. Feldman is also the principal investigator and director of the first-ever FDA-approved human clinical trial in which stem cells are injected directly into the spinal cords of ALS patients. More than 30 patients have received stem cells in two FDA-approved clinical trials, and the preliminary results are promising: the injected cells seem to have either improved or slowed disease progression in several patients.

Dr. Feldman is a great mentor and one of her accomplishments is the training of scientists and neurologists. She has mentored 9 Ph.D. students and more than 100 postdoctoral fellows and neurologists to specialize in the understanding and treatment of neuromuscular diseases, with an emphasis on ALS. Hopefully, Dr. Feldman’s research will help to create a future free of ALS.

Keep up with the latest research from the Feldman lab here.

]]>
2103
Clinic Q&A: Nurse & Nerve Center Sandy Lemkin https://www.umich-als.org/clinic-qa-nurse-nerve-center-sandy-lemkin/ Wed, 10 May 2023 17:34:11 +0000 https://www.umich-als.org/?p=1993 The theme for Nurses Week this year is “You Make a Difference.” In our own Pranger ALS Clinic is a perfect example of someone who not only makes an incredible difference in the lives of so many ALS patients and their families but also impacts her coworkers and how effectively are clinic operates.

Portrait of Sandy Lemkin, Pranger ALS Clinic Clinical Care Coordinator

Sandy Lemkin

“Sandy Lemkin truly is the nerve center of our clinic,” explains Pranger ALS Clinic Director Stephen Goutman, M.D., M.S. “Her tireless passion to care for and support those suffering from a diagnosis such as ALS serves as inspiration to myself, our team, and countless people affected by the disease.  She very much makes a difference.”

We sat down with Pranger ALS Clinic Clinical Care Coordinator Sandy Lemkin, BBA, BSN, RN, to learn more about what makes this human dynamo tick.

What inspired you to become a nurse?

Initially, I got a business degree and worked for a number of years in the automotive industry and at IBM. After a while, I realized that I wasn’t feeling fulfilled and didn’t want to “just push papers.” I wanted to help people.

My college roommate had become a nurse and seeing her in action really inspired me. I decided I was going back to school to get my nursing degree and help people.

What do you like best about what you do?

There are so many reasons. I love multitasking. I like the challenge of having to do a lot of things at one time, which was what made me successful in business as well. As a nurse, you definitely have a lot of things going on all at the same time.

Also, I love working with a team and helping to lead the team. We have an incredible group at the Pranger ALS Clinic.

Then there is the helping people part that I mentioned brought me to the nursing profession. I like developing processes and programs that help patients, especially terminal patients, like those with ALS, navigate their care – providing them with education, information, and support to go through a tough journey like ALS.

photo of Sandy Lemkin with college roommates

Lemkin with her college roommates. Lois Martonen (with her on the right) inspired her to become a nurse.

What do you wish everybody realized or understood about nursing? 

Generally, when you tell people you are a nurse, they’ll ask something like: “What hospital do you work at?” What I want people to recognize – and this is what I tell nursing students or people who are thinking about going into nursing – is that nursing is not just about being at a patient’s bedside. For instance, Jayna Duell, our ALS Clinical Research Coordinator, collects data and monitors research projects in our ALS clinical studies program. Nurses can be so many things. People should know that we encompass many aspects of health care, not just direct patient care.

You are the Pranger ALS Clinic Clinical Coordinator. What does that mean?

The team likes to consider me as the one who steers the ship. I am the main point of contact for patients and, as I explain to patients, I have a whole team that supports me in case I don’t have the answer to their questions. So, really it is navigating care for a patient and navigating their program to make sure that their care needs are being met in the appropriate amount of time.

How long have you been working in the Pranger ALS Clinic? What brought you here?

It has been 24 years now at Michigan Medicine, but I have been at the Pranger ALS Clinic for seven. My anniversary is actually this month. Before, I was a research project manager in Cardiovascular. I saw the posting and missed being in Neurology (I worked for seven years in neurogenetics), plus it was a clinical care coordinator position, which was a new challenge for me.

photo of Sandy Lemkin at her MSN graduation with fellow classmate Courtney Keatting

Lemkin at her MSN graduation with fellow classmate Courtney Keatting

What did you miss about Neurology?

I really missed the patient population. Neurologic issues can be a gray area of health care because there is so much we don’t know or don’t know how to fix. So much to be discovered. I wanted to be back helping these patients, who are hard to diagnose or who are facing a difficult diagnosis, like ALS. Right now, we don’t know how to successfully treat a lot of neurologic conditions.

Patients have to learn to live with these conditions, whereas in other departments —Cardiovascular, Orthopedics, etc. — you can usually fix something. This is not true here, so the patients are left with a big challenge.

This is what I wanted to be a part of.

This month is ALS Awareness Month. What do you wish that everyone knew about the disease? 

First and foremost, I wish people understood that ALS is different for every patient. This is something I try to explain to patients when they are first diagnosed.

One person’s experience with ALS is not going to be another’s. That’s why we approach every ALS patient in a different way, based on their needs and that of their loved ones and caregivers. It’s really an individualized diagnosis and should not be stereotyped to think that one person’s journey with ALS is going to be the same as another’s.

What advice would you give someone who knows a patient with ALS? How can they best support that person and their families?

Don’t wait for them to ask for help, offer help. They really need it, and they are scared to ask for it because they don’t want to burden anyone. Just reach out to them to say, “How can I help you? Can I make any meals? Do you need me to come over and watch your loved one or run errands?” Just offer help, and don’t wait for them to reach out.

Lemkin with her son Brendan, and his girlfriend Sarah Anderson

It’s also Nurses Week, with International Nurses Day coming up this weekend. How can we better support nurses?

First and foremost, just say “thank you” and appreciate what we do. I think that a lot of people recognize that we are the ones steering their care. We work side by side with doctors, so patients and their loved ones should appreciate what we are telling them. We are backed by physicians and other care team members, and the answers or care we are providing are coming from them as well.

What do you like best about working in the Pranger ALS Clinic?

I love our entire team. It really is amazing how well we all work together. Everyone who works with us really has to want to be there because it’s such a hard diagnosis. Most of us have been working together for a very long time. The dedication of our team and our incredible patient population is what I like best about working here.

]]>
1993
10 Key Facts About ALS in 2023 https://www.umich-als.org/10-key-facts-about-als-in-2023/ Mon, 08 May 2023 17:54:29 +0000 https://www.umich-als.org/?p=2002 Last year, Dr. Eva Feldman published a seminal ALS seminar in the top academic journal The Lancet.  In honor of ALS Awareness Month (May), she pulled out the ten key facts that are important to know in 2023.  Some even surprise some researchers and clinicians.

1.  There are multiple types of ALS.

They are based on the body parts the disease affects when it initially shows up. Bulbar and Spinal are the two most common forms.  Bulbar onset initially affects the muscles controlling speech and swallowing.  Spinal onset initially affects muscles controlling the arms and legs.  There are several additional less common subtypes of ALS.

Figures 1 A & B from Dr. Feldman’s ALS Seminar in The Lancet

 

The Lancet, Figure 1 A: a schematic showing UMNs (blue), which relay signals from the motor cortex to the LMNs (yellow), which relay signals to the muscles.

The Lancet, Figure 1 A: a schematic showing UMNs (blue), which relay signals from the motor cortex to the LMNs (yellow), which relay signals to the muscles.

2.  At the cellular level, ALS is characterized by degeneration of upper and/or lower motor neurons (nerve cells control muscle contraction).

Upper motor neurons connect the brain to the spinal cord, whereas lower motor neurons connect the spinal cord to the muscles.

3.  ALS is progressive and fatal 100% of the time.

Muscle weakness spreads from the initial onset to neighboring muscles, and so forth. This continues until patients are unable to swallow and eventually breathe.  The progression of ALS is very individual to each patient.

The Lancet, Figure 4 A: King's staging of ALS, which rates the progression of the disease into four stages

The Lancet, Figure 4 A: King’s staging of ALS, which rates the progression of the disease into four stages

4. In addition to muscle weakness, up to 50% of patients with ALS can also present with changes in cognition and behavior.

These cognitive and behavioral changes support the concept that amyotrophic lateral sclerosis is a global neurodegenerative disease along the same continuum as frontotemporal dementia.

The Lancet, Figure 1 C: amyotrophic lateral sclerosis occurs on a continuum with frontotemporal dementia

The Lancet, Figure 1 C: amyotrophic lateral sclerosis occurs on a continuum with frontotemporal dementia

5. ALS is put into two categories based on family history.

Familial ALS occurs in patients with a family history of the disease (about 15% of cases), ALS can also occur in patients without a family history of the disease, called “sporadic ALS

The Lancet, Figure 4 C: a schematic overview of factors that affect amyotrophic lateral sclerosis risk (onset) and prognosis

The Lancet, Figure 4 C: a schematic overview of factors that affect amyotrophic lateral sclerosis risk (onset) and prognosis

6.  There are over 40 known ALS genes.

The most common mutations are to genes C9orf72SOD1TARDBP, and FUS. About 70% of familial and 15% of sporadic ALS cases are associated with a mutation to a known ALS gene.

7.  Environmental and occupational hazards are believed to have an impact on ALS risk and progression.

Veterans have a higher-than-normal rate of ALS.  Last year, we found that production occupations have a higher risk of ALS due to exposure to toxins.

8.  What exactly happens in the body that causes ALS is not completely understood.

However, research suggests that ALS impairs multiple cellular processes, including RNA, protein, and mitochondrial metabolism, trafficking (movement of cargo within neurons), DNA repair, and inflammation.

The Lancet, Figure 3: An ALS differential diagnosis chart

The Lancet, Figure 3: An ALS differential diagnosis chart

9.  ALS is incurable.

Treatment is focused on managing symptoms and strategies to improve quality of life. Therapies that can potentially lengthen life in some patients include riluzole, edaravone, non-invasive ventilation, and gastrostomy tube (feeding tube). Research is actively seeking and testing novel therapies.

10.  We believe that we can one day make ALS a preventable disease.

(not in The Lancet)

The Lancet ALS Seminar in Full

]]>
2002
Clinic Q&A: The Power of Social Work with Darla Goulet https://www.umich-als.org/clinic-qa-the-power-of-social-work-with-darla-goulet/ Thu, 30 Mar 2023 18:40:27 +0000 https://www.umich-als.org/?p=2028 Few professions match the powerful impact of striving to empower and improve the lives of those around them the way social work can. There is a very special person who has been filling this crucial function for the past seven years at the Pranger ALS Clinic and the University of Michigan Health’s Department of Neurology, Darla Goulet, MSW.

We sat down recently with Darla Goulet, MSW, to learn more about the woman behind the magic.

photo of Darla Goulet

Darla Goulet, MSW

What inspired you to become a social worker?

I guess I have always been a bit of a social worker, even before I knew that was what I was going to do.

However, I wasn’t driven to go back to school to become one until my mom was diagnosed with cancer and was moved into hospice.  That was back in the ‘80s when the idea of hospice was new, and she was one of the first people in all of Michigan to be moved there.  I was blown away by the impact of her social workers, and how they not only helped my mom, but our family as well.

What do you like best about what you do?

I really love to educate, and for social work, education is huge.  Social workers are always teaching and helping people to understand what is happening and understand the resources available to them.  The role of the social worker is unique within medicine because we are not trying to fix anyone.  We are giving people the strategies and tools to help themselves.  I like that I can help people find their strengths and be able to navigate some pretty powerful stuff on their own, with just a little bit of help.  I think it’s great to see people, even in a really tough position, become advocates for themselves.

You first came to U-M through the Pranger ALS Clinic.  Why ALS?

Pretty much all my work in social work has been focused on end-of-life care, terminal illness, and that kind of thing. So, it seemed like a good fit.  At the time I didn’t know much about the disease, but it was something I was interested in.

What is the role of a social worker in a multidisciplinary clinic like the Pranger ALS Clinic?

I would say that there are two roles for a social worker at any multidisciplinary clinic, the primary one being to assist patients and their families, not just with resources, but with navigating a difficult system. Our health system is complicated in so many ways.

For those affected by ALS and other fatal diseases, there is also the end-of-life piece, which changes a lot in life, sometimes in unexpected ways.  We talk a lot in the clinic about anticipatory grief and how a progressive disease specifically affects the lives of patients and those close to them.

I have heard patients describe this change in a way that is spot on — before the disease their lives were big and broad, but with ALS everything gets narrower.  Their identity changes, relationships change, and roles change.

There is a lot of discussion surrounding that adjustment.  I also have conversations about hospice and what that means, along with palliative care.

People often ask me what it is like to die from this disease.  There are a lot of tough conversations surrounding death as it relates to ALS.

How do you handle those difficult conversations?

I hope that empowering patients with information will help take away some of the fear because, as you can imagine, there is always some fear associated with death.  After we speak, oftentimes they say: “Okay, I feel better,” “I didn’t know it would be like this,” or “I didn’t know hospice could provide this.” I think that it is often a relief to be given a safe place to ask those questions.

A key part is letting patients drive the conversation and ask questions.  Some people don’t want to know the details, and that’s okay.

Part of the Pranger ALS Clinic team, ready to run

You mentioned you have two roles, what is the second?

The other role of social work in any multidisciplinary clinic that works with such a complex population is to support my colleagues.  It’s a tough job, and there is a lot of compassion fatigue.  So, I also spend time talking to the staff.

What do you wish everyone knew about ALS?

People have heard of Lou Gehrig’s disease or ALS, but not a lot of them truly know what it is, in part because it isn’t common.

I would like people to learn what the disease is about and what it means to have it.

There is the functional decline, but there is also all the grief and pain that goes along with it.  ALS has emotional, spiritual, and, sometimes, physical pain, which affects not only the patient but everyone who loves that person.

What are some of the biggest challenges you see for those suffering from ALS?

Over the years, I often hear that patients and families feel isolated.  They get the diagnosis, and maybe friends and family are right there in the beginning, but as time goes on, people start to fall off until no one is coming around.

It ends up being a really isolating journey.

The other piece is the limited resources for those with ALS.  Don’t get me wrong, there are some great resources, but they are limited.

I think one of the biggest challenges people face is not having enough caregiving at home, which can be an expensive cost

How can those who know someone or a family dealing with ALS best support them?

I think it is incredibly important for people living with ALS and their families to have support because, as I said, ALS can be very isolating.  That support can look very different depending on the situation.  It can be hands-on care, it can be asking what tasks need to be done around the house, and it can be grocery shopping.  It can be asking, “Can I call you to just offer support?” Or, if they are spiritual, “Can I sit and pray with you?”

The important piece is making the patient not feel alone.  People can be very uncomfortable when someone they know is diagnosed with such a disease, so this is where education comes in again.   Helping people learn about the disease will allow them to feel more comfortable in providing support.

The Goulet Family, including her husband, five kids, one son-in-law, and two granddaughters

What do you like best about working in the Pranger ALS Clinic?

We have an amazing team and amazing providers.

I am truly inspired by their knowledge, their empathy, the compassion they show, and just their desire to help the folks we serve.  I think if we didn’t have such an incredible team, it would be hard to stay because this is a tough job.  I’ve been here for seven years!  This team makes all the difference.

I also love working with patients and their families.  Not only do I get to teach them, but they teach me, which is awesome. Anytime I have clinic, I learn something new and am inspired.  Honestly, I think people with ALS and their families are some of the most resilient people.  They readily adapt to everything.

Our brains like time to adjust to loss, and they don’t have that, but they adapt.  Of course, they have bad moments, but the majority of our folks find peace in the journey and live life to the fullest.  It is very inspirational to be part of this.  I mean, what an honor to be allowed into their lives, for them to share with someone who was initially a stranger, and allow me to be part of their journey.  It is incredible.

]]>
2028
Journal Cover Features Latest ALS Research https://www.umich-als.org/journal-cover-features-latest-als-research/ Mon, 27 Mar 2023 18:54:44 +0000 https://www.umich-als.org/?p=2035 A team led by Pranger ALS Clinic Director Stephen Goutman, M.D., M.S., and Director of both the ALS Center of Excellence and NeuroNetwork for Emerging Therapies Eva Feldman, M.D., Ph.D., recently published a study in the academic journal Muscle & Nerve that looked at whether body mass index (BMI) is associated with ALS Survival.  The journal not only published the findings but featured them on its March 2023 cover.

Muscle & Nerve’summary of the paper in “Issue Highlights:”

3 BODY MASS INDEX ASSOCIATES WITH AMYOTROPHIC LATERAL SCLEROSIS SURVIVAL AND METABOLOMIC PROFILES (PAGE 208)

Weight loss early in the course of amyotrophic lateral sclerosis (ALS) is associated with shorter survival. This study assessed changes in body mass index (BMI) in individuals with ALS prior to the development of symptoms, and found that BMI decreased by more than 25% in the 10 years preceding the diagnosis of ALS, and that most of this occurred in the 5 years prior to diagnosis. They also found relationships between BMI, BMI trends, and survival. Certain metabolomic profiles were associated with BMI trajectories. An accompanying editorial by Drs. Dupuis and Chio reviews the complex and sometimes contradictory literature on BMI and ALS, and discusses the metabolomic profiles identified in the current paper.

READ THE FULL PAPER ]]>
2035
Every Day is Recycling Day at the NeuroNetwork https://www.umich-als.org/every-day-is-recycling-day-at-the-neuronetwork/ Sat, 18 Mar 2023 19:35:23 +0000 https://www.umich-als.org/?p=2041 For Global Recycling Day the NeuroNetwork for Emerging Therapies shares all the ways the reduce, reuse, and recycle in the lab.

When speaking about the environment, the NeuroNetwork for Emerging Therapies is usually connected with their work looking at how the world around us affects neurologic disease, especially ALS.  Man people don’t realize that in the lab, they worry just as much about how they affect the environment, as how it affects us.

Last year the NeuroNetwork lab was granted Platinum status by the University of Michigan’s Office of Campus Sustainability(link is external)‘s Planet Blue(link is external) initiative, the highest (best) rating one can receive.  In honor of the 6th annual Global Recycling Day(link is external), the NeuroNetwork “green team” shared the ways they reduce, reuse and recycle in the lab.

 

How we reduce, reuse & recycle:

]]>
2041
ALS Association Awards Dr. Stephen Goutman Two Grants https://www.umich-als.org/als-association-awards-dr-stephen-goutman-two-grants/ Thu, 16 Feb 2023 19:50:58 +0000 https://www.umich-als.org/?p=2061

Two separate grants, aimed at ALS prevention and increasing clinical trial access and efficiency, were recently awarded to Pranger ALS Clinic Director Stephen Goutman, M.D., M.S.

Stephen Goutman, M.D., M.S.

Award to Prevent ALS:

The first was one of only six funded projects with the “ambitious goal” of preventing ALS.  The Pranger ALS Clinic director, along with Eva Feldman, M.D., Ph.D., believe they will one day be able to do just that.

“We will never have a world without ALS until we can prevent it,” said ALS Association Chief Mission Officer Dr. Neil Thakur. “And for that, we need the science to show us the best way to reduce people’s risk of developing the disease, whether they carry ALS genes or not. This research will move us forward in reaching this ambitious goal.”

To make this dream a reality Dr. Goutman and the ALS team seek to understand the environmental factors, genetics, and immune system mechanisms that affect ALS risk and survival.

READ MORE ABOUT THE GRANT TO PREVENT ALS HERE

Inaugural Trial Capacity Awards:

The second award is part of $5 million in grants the ALS Association is giving away to boost clinical trial capacity and speed.  Named the inaugural Trial Capacity Awards, they will support the efforts of 13 established and emerging ALS Clinical Trial sites, including the Pranger ALS Clinic.  Their purpose is to increase both the quantity and diversity of those living with ALS who have the opportunity to participate in a study, as well as improve the efficiency and pace at which these studies are conducted.

“There is an urgent need to increase the number and capacity of sites to complement the increase in ALS clinical trials that we are seeing,” said Dr. Paul Larkin, director of research at The ALS Association. “Expanding clinical trial capacity will allow potential new therapies to be tested faster and will improve trial accessibility for people with ALS in currently underserved areas.”

READ MORE ABOUT THE INAUGURAL TRIAL CAPACITY AWARDS

]]>
2061
Making Music With His Own Eyes https://www.umich-als.org/making-music-with-his-own-eyes/ Wed, 01 Feb 2023 19:57:16 +0000 https://www.umich-als.org/?p=2066 Michigan Medicine’s Health Lab blog shares the inspiring story of how a Pranger ALS Clinic patient’s ingenuity has allowed him to continue doing what he loves despite an ALS diagnosis.

MAKING MUSIC WITH ONLY HIS EYES

ALS didn’t keep a man from his lifelong passion for producing music

Author| Noah Fromson

photo of Jordan Weston producing music from Michigan Medicine's Health Lab blog
Jordan Weston producing music

A dream-like synth opens the song, as a warmer electric piano provides a complimentary counterpoint line. When the beat arrives, instruments begin to drop out. During these breakdowns, the imaginative “830a” feels like a conversation, almost as if the music is underscoring the listener’s thoughts.

Music flowed through Jordan Weston at a young age. His parents played Al Green and Lauryn Hill while they would clean the house; all his father’s cars had upgraded sound systems.

On a black-and-blue Yamaha keyboard, Weston’s cousin, James, wrote songs while a teenage Jordan watched.

“He started teaching me how to add instruments together to make a song,” said Weston, 32, who lives in Ypsilanti, Mich. “After that, I pretty much took from there.”

Weston began making his own music using a program called FL Studio. For 17 years, he messed around on the keyboard; building lush, layered songs that crossed genres: jazz, trap, emo – what he calls “freestyle.”

In 2018, Weston noticed a twitch in his left arm. When he worked out, the arm would tire faster than his right. Soon, he could no longer curl a 10-pound weight. The diagnosis of amyotrophic lateral sclerosis, a fatal and progressive neurodegenerative condition known commonly as ALS, came in June 2018.

“I felt sad and confused and scared,” Weston said. “I just had a blank mind for a while knowing I would lose my ability to move. It got harder and harder to make music as I lost the ability to use my hands.”

The Centers of Disease Control and Prevention estimates that almost 10 in 100,000 Americans have ALS. No treatment currently exists to stop or reverse the disease.

Weston found a way to continue his musical journey with a QuadStick, a hands-free controller powered by the user blowing into a tube. But when a tracheostomy got in the way of using his mouth, he found another way to produce.

Through a sensor bar on his tablet, the Tobii DynaVox I-16 tracks Weston’s eye movements, allowing him to control the music software and build out his songs. He posts some of his music to a YouTube channel.

photo of Jordan Weston from the Michigan Medicine Health lab blog
Credit to Jordan Weston

“Making music has been something Jordan has done practically since I’ve known him, which was in high school,” said Tiffany Weston, Jordan’s wife. “I’m grateful that he is able to continue to do something to express his creativity. We enjoy hearing the music he makes throughout our home. Even our children hum the tunes while he’s creating.”

Weston has been a patient at Michigan Medicine’s Pranger ALS Clinic since his diagnosis, where he receives regular multidisciplinary care. As his mobility declines, Weston has relied more on virtual care.

“The ingenuity of people living with ALS always amazes me,” said Stephen Goutman, M.D., M.S., a neurologist and director of the Pranger ALS Clinic at University of Michigan Health.

“Even in the face of this difficult illness, individuals with ALS redefine what it means to live and find quality in very personal ways. Jordan’s love of music provides a channel for his creativity and imagination. It also teaches us to appreciate our abilities and to be creative. There are so many ways technology can be applied to improve the quality of life for our patients.”

Music is one way Weston stays busy, in addition to watching television and helping others when he has useful knowledge. Family and friends, Weston says, have been very supportive — but he knows others experience the harshness of ALS with fewer resources.

“Some people may just look at the name and think nothing of it,” Weston said. “People don’t realize how it feels to have your own body take away your ability to move and do the stuff you used to. A lot of people take for granted what they can do. And people going through ALS need emotional and physical support. Having support can soften the intensity of what families go through when dealing with ALS.”

]]>
2066
Dr. Stephen Goutman featured with Zac Brown Band’s John Driskell Hopkins on Brain & Life Podcast https://www.umich-als.org/dr-stephen-goutman-featured-with-zac-brown-bands-john-driskell-hopkins-on-brain-life-podcast/ Thu, 15 Dec 2022 18:36:38 +0000 https://www.umich-als.org/?p=2073

The American Academy of Neurology’s (AAN) podcast features John Driskell Hopkins, musician and founding member of the Zac Brown Band who was diagnosed with amyotrophic lateral sclerosis (ALS) last year. Dr. Stephen Goutman then discusses the complexities of an ALS diagnosis, future treatment, and research initiatives.

From the Brain & Life website:

Hop on a Cure for ALS with John Driskell Hopkins

CLICK HERE TO LISTEN TO THE PODCAST 

photo of John Driskell Hopkins

Photo courtesy of John Driskell Hopkins

“In this episode Dr. Daniel Correa speaks with John Driskell Hopkins, musician and founding member of the Zac Brown Band. John shares his story of being diagnosed with amyotrophic lateral sclerosis (ALS) in 2021 and what he is doing to spread awareness about this rare disease. Next, Dr. Correa talks with Dr. Stephen Goutman, a neurologist and associate professor in the Department of Neurology and Director of the Pranger ALS Clinic and ALS Center of Excellence at Michigan Medicine. Dr. Goutman discusses the complexities of an ALS diagnosis, future treatment, and research initiatives.

photo of Dr. Stephen Goutman

Stephen Goutman, M.D., M.S.

“A special thank you to John Driskell Hopkins for permission to feature the title track “Daylight” from his album in this week’s episode. Available on Spotify and Soundcloud.”

CLICK HERE FOR EPISODE TRANSCRIPT

]]>
2073
Roberta Flack ALS Diagnosis Article Features Dr. Stephen Goutman https://www.umich-als.org/roberta-flack-als-diagnosis-article-features-dr-stephen-goutman/ Wed, 16 Nov 2022 18:44:32 +0000 https://www.umich-als.org/?p=2080

Recently the “Killing Me Softly” singer announced her ALS diagnosis which has left her unable to sing.  Healthline sat down with Stephen Goutman, M.D., to discuss the effect of the disease and new ALS research on the horizon.

Article from Healthline.com:

ALS: Roberta Flack Says Disease Has Left Her Unable To Sing

By Shawn Radcliffe  — Fact checked by Dana K. Cassell

photo of Roberta Flack

Axelle/Bauer-Griffin/FilmMagic/Getty Images

  •  Roberta Flack, known for songs such as “Killing Me Softly,” has been diagnosed with ALS.

  • Her spokesperson said this week that the disease has left her unable to sing.

  • ALS causes nerve cells that control voluntary muscles to stop working and die.

Grammy-winning musician Roberta Flack has been diagnosed with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.

This progressive nervous system disease has made it “impossible [for her] to sing and not easy to speak,” her spokesperson said in a statementsent to CNN on Monday. “But it will take a lot more than ALS to silence this icon.”

While ALS is a relatively rare disease, notable athletes, entertainers, politicians, and thousands of Americans have been affected by this disease.

Awareness of ALS has increased in recent years, in part due to the Ice Bucket Challenge, which helped raise millions of dollars for research, according to the ALS Association.

ALS causes nerve cells that control voluntary muscles to stop working and die. This can lead to weakness and paralysis in the muscles of the hands, arms, legs or feet, as well as in the muscles that control speech and swallowing.

There is no cure for this fatal disease.

What is ALS?

ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing the cells to deteriorate and eventually die.

The disease specifically affects motor neurons, which control muscles that govern voluntary movements. When motor neurons die, the brain is no longer able to activate those muscles.

This can cause specific muscles to become weak and leads to paralysis. As a result, people may lose the ability to move, eat, speak and breathe.

In 2017, there were an estimated 18,000 to 32,000 cases of ALS in the United States, according to the Centers for Disease Control and Prevention.

How does ALS affect people?

The most common initial symptom of ALS is muscle weakness — which is usually painless.

Dr. Stephen Goutman, director of the Pranger ALS Clinic and associate director of the ALS Center of Excellence at Michigan Medicine in Ann Arbor, said muscle weakness typically starts in one region of the body and then spreads to other areas.

Symptoms of ALS generally start gradually, but can vary among people, depending on which motor neurons are affected. Symptoms include:

  • weakness or fatigue in the legs, feet, arms or hands
  • tripping and falling
  • dropping objects or other hand clumsiness
  • muscle cramps or twitches
  • slurred speech
  • swallowing difficulty
  • uncontrollable crying or laughing

Goutman said ALS doesn’t just affect the motor neurons. Many people with the disease also experience cognitive changes such as decision-making difficulties, personality changes or irritability.

Due to the degeneration of the motor neurons, ALS eventually affects chewing, swallowing, speaking, and breathing.

“Because of the progressive nature of the disease, it is unfortunately fatal, mostly because of the difficulties with breathing,” said Goutman.

On average, people with ALS live from 3 to 5 years after they develop symptoms, although some people live longer.

ALS doesn’t usually affect bladder control, vision or other senses because these are controlled by different types of neurons.

Who is most at risk from ALS?

Certain factors increase the risk of developing ALS, including:

  • Heredity. About 5-10% of ALS cases occur within families and are caused by genes known to be linked to ALS.
  • Age. ALS typically occurs in people between 55 and 75 years of age, although cases can occur in younger people.
  • Sex. Men have a slightly higher risk than women of developing ALS. Familial ALS occurs equally often in men and women.
  • Genetics. Some studies suggest that 60% of the risk of non-inherited ALS is due to genetic factors. People who have these gene variations may be more likely to develop ALS.

In addition, research has found a possible link between ALS and certain environmental factors. More research is needed to fully understand these connections.

  • Smoking. Some studies indicate that smokers have a higher risk of developing ALS than people who never smoked.
  • Environmental exposures. Research suggests a possible link between ALS risk and exposure to heavy metals (such as lead and mercury), chemical solvents, radiation, pesticides and other toxins.
  • Military service. Studies indicate that people who served in the military have a higher risk of developing ALS compared to those who did not serve in the military.
  • Occupation. Research suggests that the ALS risk is higher among people with certain jobs, such as construction, manufacturing, mechanical or painting.
  • Contact sports. Studies have found a higher risk of ALS among people who play competitive contact sports that involve repetitive head and neck trauma, such as hockey, football and soccer.
]]>
2080